کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3032003 1579265 2016 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease
ترجمه فارسی عنوان
ناهنجاری های تصویربرداری مرتبط با آمیلوئید از آزمایشات پلانزوماب برای بیماری آلزایمر
کلمات کلیدی
ناهنجاریهای تصویربرداری مرتبط با آمیلوئید، بیماری آلزایمر، آزمایشات بالینی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی عصب شناسی
چکیده انگلیسی

IntroductionSolanezumab, a humanized monoclonal antibody that binds soluble amyloid beta peptide, is being developed for treatment of Alzheimer's disease (AD).MethodsPatients (n = 2042) with mild and moderate AD were randomized 1:1 to 400-mg solanezumab or placebo infusion every 4 weeks for 80 weeks and 1457 patients entered an open-label extension. Magnetic resonance imaging scans monitored for amyloid-related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related imaging abnormalities-hemorrhage/hemosiderin deposition.ResultsSixteen patients (solanezumab, n = 11; placebo, n = 5) developed ARIA-E during the double-blind phase, and 7 patients developed ARIA-E during the open-label extension as of July 31, 2014. Unique cases are discussed including solanezumab patients who were given solanezumab, while ARIA-E was present and a patient who developed ARIA-E during placebo treatment and again during solanezumab treatment.DiscussionAsymptomatic ARIA-E was detected in solanezumab-treated and placebo-treated AD patients. ARIA-E occurs infrequently during solanezumab and placebo treatments but may occur repeatedly in some patients.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring - Volume 2, 2016, Pages 75–85
نویسندگان
, , , , , , , ,